“…GA, a unique post-translational product of the glycosylation of albumin, has been shown to be a useful biomarker in: (i) clinical conditions in which the dosage of glycated hemoglobin (HbA1c) does not reflect glycemic compensation, such as chronic renal failure, gestational diabetes, dialysis complications, hemorrhages, recent transfusions, hemolytic anemia and hemoglobin variants [ 6 , 9 , 10 , 11 , 12 , 13 ]; (ii) patients with poorly controlled diabetes and with postprandial hyperglycemia in order to monitor short-term glycemic fluctuation [ 14 , 15 ]; (iii) diabetic patients for monitoring therapeutic response [ 16 , 17 , 18 , 19 ]; (iv) detecting prediabetes even in the presence of normoglycemia, which is a priority because the effectiveness of this lifestyle intervention is lost if diabetes has already developed [ 20 , 21 ]. It is well known that fructosamine represents all the circulating glycated proteins, therefore Glycated Albumin is biochemically recognized as a form of fructosamine [ 14 ].…”